The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study

Table 2 Multivariate analyses of risk of malignant diseases among biologic users in comparison with matched controls

		All	TNF-α inhibitor ¹ users	Adalimumab ²	Etanercept ³	Rituximab
Biologics	Event, number	89	89	8	71	0
	Total person-years	16650.63	16624.36	2203.45	10363.75	26.27
	IR per 1000 (95% CI)	5.35 (4.23, 6.46)	5.35 (4.24, 6.47)	3.63 (1.11, 6.15)	6.85 (5.26, 8.44)	-
nbDMARDs⁴	Event, number	486	485	51	309	1
	Total person-years	65587.93	65485.91	8763.78	41209.78	102.02
	IR per 1000 (95% CI)	7.41 (6.75, 8.07)	7.41 (6.75, 8.07)	5.82 (4.22, 7.42)	7.50 (6.66, 8.33)	9.80 (0.00, 29.01)
	HR (95% CI)	0.63 (0.49, 0.80)	0.63 (0.50, 0.81)	0.61 (0.28, 1.33)	0.83 (0.62, 1.10)	-
	IRR (95% CI)	0.72 (0.58, 0.90)	0.72 (0.58, 0.91)	0.62 (0.30, 1.31)	0.91 (0.71, 1.18)	-
	P-value	0.0046	0.0049	0.2147	0.4926	-

¹Includes all patients who have used TNF-α inhibitors, with or without disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids, in comparison with matched controls. ²Use of adalimumab alone, with or without DMARDs or corticosteroids, in comparison with matched controls. ³Use of etanercept alone, with or without DMARDs or corticosteroids, in comparison with matched controls. ⁴Indicates the event number and total observed person-years of matched subjects from THE nonbiologic DMARDS (nbDMARDs) cohort for each of those using different types of TNF-α inhibitors and rituximab. HR, hazard ratio; IR, incidence rate; IRR, incidence rate ratio.

ISSN: 1478-6362